Advertisement
Cleveland Clinic is one of six hospitals nationwide leading the Musculoskeletal Tumor Registry initiative
Every year, approximately 15,000 new cases of sarcoma are diagnosed in the United States. Sarcoma, a rare cancer that originates in connective tissue, accounts for about 1% of all cancer diagnoses in adults and about 15% of pediatric cancer diagnoses.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The Musculoskeletal Tumor Registry (MsTR), an initiative led by the American Academy of Orthopaedic Surgeons (AAOS) in collaboration with the Musculoskeletal Tumor Society (MSTS), was launched in early 2019. MsTR enables orthopaedic oncologists to share data, procedures and patient-reported outcomes about sarcoma and other rare connective disease tumors.
Cleveland Clinic is among six major academic medical centers chosen to participate in this program. Nathan Mesko, MD, one of the MsTR surgeon leaders, recently discussed the collaboration and its clinical implications for treating sarcoma patients in a Q&A with AAOS.
Nathan W. Mesko, MD, is the Center Director of Musculoskeletal Oncology in the Orthopaedic and Rheumatologic Institute at Cleveland Clinic. He is also co-director of the Sarcoma Center in the Taussig Cancer Institute at Cleveland Clinic.
Advertisement
Polygenic risk score could help predict who will develop this aggressive breast cancer
New guidelines offer insight into emerging therapies, dental issues and more
Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy
Research demonstrates improved overall survival for patients receiving comprehensive treatment for breast cancer in addition to radiation or surgical intervention for brain cancer
Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’
Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates
Extent of baseline burden impacts progression-free and overall survival
Further study warranted to better understand the clinical implications of these findings